RU2435851C2 - Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили - Google Patents
Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили Download PDFInfo
- Publication number
- RU2435851C2 RU2435851C2 RU2010104618/10A RU2010104618A RU2435851C2 RU 2435851 C2 RU2435851 C2 RU 2435851C2 RU 2010104618/10 A RU2010104618/10 A RU 2010104618/10A RU 2010104618 A RU2010104618 A RU 2010104618A RU 2435851 C2 RU2435851 C2 RU 2435851C2
- Authority
- RU
- Russia
- Prior art keywords
- skeleton
- immunostimulating
- profiles
- context
- rna sequence
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 claims abstract 8
- 229920000642 polymer Polymers 0.000 claims abstract 5
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 4
- 150000004713 phosphodiesters Chemical group 0.000 claims 4
- 108091027075 5S-rRNA precursor Proteins 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 cationic lipid Chemical class 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 abstract 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 *C1**(*)S(*)CC1 Chemical compound *C1**(*)S(*)CC1 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96444807P | 2007-08-13 | 2007-08-13 | |
| US60/964,448 | 2007-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010104618A RU2010104618A (ru) | 2011-09-20 |
| RU2435851C2 true RU2435851C2 (ru) | 2011-12-10 |
Family
ID=40351228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010104618/10A RU2435851C2 (ru) | 2007-08-13 | 2008-08-08 | Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8128944B2 (enExample) |
| EP (1) | EP2179039B1 (enExample) |
| JP (1) | JP4847609B2 (enExample) |
| KR (1) | KR20100045508A (enExample) |
| CN (1) | CN101821392B (enExample) |
| AR (1) | AR067928A1 (enExample) |
| AU (1) | AU2008288241B2 (enExample) |
| BR (1) | BRPI0814260B8 (enExample) |
| CA (1) | CA2696630C (enExample) |
| CL (1) | CL2008002371A1 (enExample) |
| CO (1) | CO6260153A2 (enExample) |
| DK (1) | DK2179039T3 (enExample) |
| ES (1) | ES2703876T3 (enExample) |
| MX (1) | MX2010001014A (enExample) |
| NZ (1) | NZ582972A (enExample) |
| PL (1) | PL2179039T3 (enExample) |
| PT (1) | PT2179039T (enExample) |
| RU (1) | RU2435851C2 (enExample) |
| SI (1) | SI2179039T1 (enExample) |
| TR (1) | TR201820474T4 (enExample) |
| TW (1) | TW200916106A (enExample) |
| WO (1) | WO2009022216A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4847609B2 (ja) | 2007-08-13 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ |
| JP2010536907A (ja) * | 2007-08-31 | 2010-12-02 | ニューリミューン セラピューティクス エイジー | 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法 |
| WO2009105641A2 (en) | 2008-02-20 | 2009-08-27 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| WO2013012875A2 (en) | 2011-07-18 | 2013-01-24 | Mount Sinai School Of Medicine | Bacterial rnas as vaccine adjuvants |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| MX2020006243A (es) | 2017-12-15 | 2020-09-03 | Bayer Animal Health Gmbh | Oligonucleotidos inmunoestimulantes. |
| WO2024030844A1 (en) * | 2022-08-01 | 2024-02-08 | University Of Mississippi | Choline carboxylic acid based ionic liquids as antimicrobial agents |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2127125C1 (ru) * | 1994-03-07 | 1999-03-10 | Дзе Дау Кемикал Компани | Биологически активные и/или целевые дендримерные конъюгаты |
| RU98100213A (ru) * | 1995-06-07 | 1999-11-27 | Супратек Фарма, Инк. | Композиции, включающие биологический агент |
| RU2185818C1 (ru) * | 2001-07-10 | 2002-07-27 | НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова | Композиция для лечения легочных инфекций |
| RU2238279C2 (ru) * | 1999-02-15 | 2004-10-20 | Ниппон Синяку Ко., Лтд. | Полинуклеотид с укороченной цепью и способ его получения |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| RU2289410C2 (ru) * | 2001-04-04 | 2006-12-20 | Корикса Корпорейшн | Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
| IL160157A0 (en) * | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
| EP1499187B1 (en) * | 2002-04-04 | 2015-06-17 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
| CN1302948C (zh) | 2002-04-12 | 2007-03-07 | 爱信艾达株式会社 | 车载装置用电源管理系统 |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US7956043B2 (en) * | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
| AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
| CA2555390C (en) * | 2004-02-19 | 2014-08-05 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| US8076068B2 (en) * | 2005-09-14 | 2011-12-13 | Gunther Hartmann | Method for determining immunostimulatory activity of RNA oligonucleotides |
| ES2536103T3 (es) * | 2005-11-25 | 2015-05-20 | Zoetis Belgium S.A. | Oligorribonucleótidos inmunoestimuladores |
| JP4847609B2 (ja) * | 2007-08-13 | 2011-12-28 | コーリー ファーマシューティカル ゲーエムベーハー | 特異的な免疫修飾プロフィールを誘発する規定されたヌクレオチド間結合との関連におけるｒｎａ配列モチーフ |
-
2008
- 2008-08-08 JP JP2010520640A patent/JP4847609B2/ja active Active
- 2008-08-08 BR BRPI0814260A patent/BRPI0814260B8/pt active IP Right Grant
- 2008-08-08 WO PCT/IB2008/002104 patent/WO2009022216A2/en not_active Ceased
- 2008-08-08 CA CA2696630A patent/CA2696630C/en active Active
- 2008-08-08 ES ES08789054T patent/ES2703876T3/es active Active
- 2008-08-08 NZ NZ582972A patent/NZ582972A/en not_active IP Right Cessation
- 2008-08-08 EP EP08789054.7A patent/EP2179039B1/en active Active
- 2008-08-08 US US12/670,697 patent/US8128944B2/en active Active
- 2008-08-08 SI SI200832023T patent/SI2179039T1/sl unknown
- 2008-08-08 KR KR1020107005451A patent/KR20100045508A/ko not_active Ceased
- 2008-08-08 RU RU2010104618/10A patent/RU2435851C2/ru not_active IP Right Cessation
- 2008-08-08 MX MX2010001014A patent/MX2010001014A/es active IP Right Grant
- 2008-08-08 CN CN2008801113989A patent/CN101821392B/zh active Active
- 2008-08-08 TR TR2018/20474T patent/TR201820474T4/tr unknown
- 2008-08-08 PL PL08789054T patent/PL2179039T3/pl unknown
- 2008-08-08 PT PT08789054T patent/PT2179039T/pt unknown
- 2008-08-08 AU AU2008288241A patent/AU2008288241B2/en active Active
- 2008-08-08 DK DK08789054.7T patent/DK2179039T3/en active
- 2008-08-12 CL CL2008002371A patent/CL2008002371A1/es unknown
- 2008-08-12 TW TW097130681A patent/TW200916106A/zh unknown
- 2008-08-13 AR ARP080103532A patent/AR067928A1/es not_active Application Discontinuation
-
2010
- 2010-02-15 CO CO10016821A patent/CO6260153A2/es not_active Application Discontinuation
-
2012
- 2012-01-30 US US13/360,894 patent/US8227447B2/en active Active
- 2012-06-12 US US13/494,216 patent/US8466124B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2127125C1 (ru) * | 1994-03-07 | 1999-03-10 | Дзе Дау Кемикал Компани | Биологически активные и/или целевые дендримерные конъюгаты |
| RU98100213A (ru) * | 1995-06-07 | 1999-11-27 | Супратек Фарма, Инк. | Композиции, включающие биологический агент |
| RU2238279C2 (ru) * | 1999-02-15 | 2004-10-20 | Ниппон Синяку Ко., Лтд. | Полинуклеотид с укороченной цепью и способ его получения |
| RU2288921C2 (ru) * | 2000-12-19 | 2006-12-10 | Калифорниа Инститьют оф Текнолоджи | Композиции, содержащие комплексы включения |
| RU2289410C2 (ru) * | 2001-04-04 | 2006-12-20 | Корикса Корпорейшн | Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах |
| RU2185818C1 (ru) * | 2001-07-10 | 2002-07-27 | НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова | Композиция для лечения легочных инфекций |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2435851C2 (ru) | Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили | |
| US10378018B2 (en) | RNA-based compositions and adjuvants for prophylactic and therapeutic treatment | |
| KR102022031B1 (ko) | 비-코딩 면역조절 dna 구조체 | |
| EP2573185A3 (en) | Lentiviral vectors and their use | |
| JP2020532955A5 (enExample) | ||
| WO2007062107A3 (en) | Immunostimulatory oligoribonucleotides | |
| WO2001093902A3 (en) | Immunostimulatory rna/dna hybrid molecules | |
| KR20050100375A (en) | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | |
| ZA202300131B (en) | Lipid nanoparticles | |
| EP2526774A3 (en) | Targeted gene delivery for dendritic cell vaccination | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| WO2008011561A3 (en) | End-modified poly(beta-amino esters) and uses thereof | |
| EP2327774A3 (en) | Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity | |
| EP2999787B1 (en) | Covalently closed non-coding immunomodulatory dna construct | |
| MX336839B (es) | Formacion de complejos de acidos nucleicos con componentes cationicos entrelazados por disulfuro para transfeccion e inmunoestimulacion. | |
| HUE025027T4 (hu) | (NuGiXmGnNv) a képletet tartalmazó nukleinsavak és származékaik mint immunstimuláns szerek/adjuvánsok | |
| EP2659912A3 (en) | Conjugate purification | |
| MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
| MX2010006610A (es) | Conjugados de factor de crecimiento de nervios y usos de los mismos. | |
| WO2011140595A3 (en) | Immunostimulatory and vaccine compositions | |
| WO2006029081A3 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
| WO2008056174A3 (en) | Novel compositions and uses thereof | |
| CN103596594A (zh) | 自身凝胶化核酸 | |
| AR039846A1 (es) | Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo | |
| EP2402442A3 (en) | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120809 |